L-3-n-butylphthalide soft capsules in the treatment of Parkinson disease dementia: A systematic review and meta-analysis of randomized controlled trials

Medicine (Baltimore). 2019 Jun;98(24):e16082. doi: 10.1097/MD.0000000000016082.

Abstract

Background: In recent years, L-3-n-butylphthalide (L-NBP) has been used for Parkinson disease dementia (PDD) to attenuate cognitive impairments in China. Therefore, we selected published and qualified clinical trials to conduct a systematic review and meta-analysis with the aim of assessing the effectiveness and safety of L-NBP in the treatment of PDD.

Objective: This systematic review and meta-analysis aimed to assess the effectiveness and safety of L-NBP in the treatment of PDD.

Methods: We searched PubMed, EMBASE, China National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP database), and Wan-Fang Database to collect eligible articles. We calculated pooled estimates of odds ratios or the standard mean deviation with 95% confidence intervals.

Results: Eight randomized controlled trials were included in our meta-analysis. Our meta-analysis showed that L-NBP combined with Western medicine (WM) had a better effect on improving cognitive dysfunction, the total effective rate, symptoms of Parkinson disease (PD), and activities of daily living function than WM alone. Regarding safety, no serious adverse events were observed in the experimental group.

Conclusion: We found that L-NBP as a complementary therapy may have a positive therapeutic effect for improving cognitive dysfunction, the total effective rate, symptoms of PD, quality of life, and the related serum factors in the treatment of PDD. Furthermore, L-NBP was a safe treatment for PDD. However, the findings of our meta-analysis may be influenced by the low quality of the included studies. We highlight the need to conduct trials with higher methodological quality.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Antiparkinson Agents / administration & dosage*
  • Antiparkinson Agents / adverse effects
  • Benzofurans / administration & dosage*
  • Benzofurans / adverse effects
  • Capsules
  • Dementia / drug therapy*
  • Dementia / etiology
  • Humans
  • Nootropic Agents / administration & dosage*
  • Nootropic Agents / adverse effects
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / psychology
  • Randomized Controlled Trials as Topic

Substances

  • Antiparkinson Agents
  • Benzofurans
  • Capsules
  • Nootropic Agents
  • 3-n-butylphthalide